Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease

Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease

Background: Neuroinflammation plays a pathogenic role in Parkinson's disease (PD). Immunotherapies that restore brain homeostasis can mitigate neurodegeneration by transforming T cell phenotypes. Sargramostim has gained considerable attention as an immune transformer through laboratory bench to...

Full description

Bibliographic Details
Main Authors: Katherine E. Olson, Krista L. Namminga, Yaman Lu, Aaron D. Schwab, Mackenzie J. Thurston, Mai M. Abdelmoaty, Vikas Kumar, Melinda Wojtkiewicz, Helen Obaro, Pamela Santamaria, R. Lee Mosley, Howard E. Gendelman
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:EBioMedicine
Subjects:
Parkinson's disease
Granulocyte macrophage-colony stimulating factor
Unified Parkinson's Disease Rating Scale
Regulatory T cells
Neuroprotection
Sargramostim
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396421001730

Internet

http://www.sciencedirect.com/science/article/pii/S2352396421001730

Similar Items